MIR21 and cholangiocarcinoma: Our data suggest that it would be useful to carry out further studies of the biomarker potential of MIR21 as a guide treatment with HSP90 inhibitors, as well as to pursue the combination of HSP90 inhibitors with MIR21 inhibitors in CCA.